Tectonic Therapeutic, Inc Investor Event Transcript, Nov 11, 2026
Tectonic Therapeutic, Inc. (TECX)
Tectonic Therapeutic expects TX45 Phase II data by end of January and plans PHILD interim data in the second half of 2027, with cash runway through the first quarter of 2029. AI summary
Conference Transcript - TECX 2026-11-11
Alise Reicin, CEO
Exactly. So, good.
Operator
All right, we can get started, so we can make sure to get through all of our questions. But great to be here with Tectonic Therapeutic. We have CEO Elise Ryzen. Great to have you here. Thanks for joining.
Alise Reicin, CEO
Thanks for the invitation.
Speaker 1
Of course, really interesting time for you guys. So, maybe we can just start with a kind of like a brief overview of kind of like what's coming and kind of, you know, how you're framing it for folks.
Alise Reicin, CEO
We have a Catalyst Rich 2027. It'll start with our... TX45, our lead program, will have Phase II data by end of January. We will not be at J.P. Morgan, and so you can expect it sometime between J.P. Morgan and hopefully end of January. So that will be data from our Phase II study in Group II pulmonary hypertension and HFPEF. We are actively enrolling our PHILD study with TX45, and we expect interim data from that study, which is a single-arm study of about 20 to 25 patients, second half of 2027. We are just about, you know, between now and the end of the year, we will start our phase 1b study with our APJ antagonist, TX2100, in patients with HHT who require hematologic support. And we should have interim data from that study, so our second program in hereditary hemorrhagic telangiectasia, by the end of 2027. And in early 2027, we'll start our phase two study in moderate to severe, into patients with HHT with moderate to severe epistaxis.
Speaker 1
Yeah, very busy time. Maybe we can just start with HHT, you know, since you've had some data recently. I think there's a lot of investor interest in HHT and sort of an appreciation that it could be a big rare disease market, but there's obviously a lot of companies and different mechanisms. So maybe just kind of like set the stage on your mechanism, kind of this sort of like thesis behind it, and then some of the initial health and volunteer data you have.
Alise Reicin, CEO
So why don't I start with HHT? Because not all investors know HHT yet. HHT is the second most common genetic bleeding disorder, impacts about 75,000 to 80,000 patients in the U.S. alone, over a million worldwide. And it's basically a disease of dysregulated angiogenesis. It's mutations in the BMP9 ALK pathway. And anti-VEGF inhibitors, anti-angiogenic agents, have been shown to work in preclinical models of the disease, and that has translated to the clinic. TX2100 is an antagonist antibody to APJ, which is an anti-angiogenic agent, but it's a more specific and selective approach to angiogenesis, so what we hope is to have the efficacy, or maybe even better efficacy than the currently used therapies, none of which are approved, because we'll have a better safety profile. And then, as I said, efficacy is as good as and maybe even better than those.
Speaker 1
Yeah. Yeah. Makes sense. And, you know, obviously, it sounds like safety is a core part of that thesis in terms of some of the healthy volunteers.
Alise Reicin, CEO
So how do the VEGF inhibitors work? AKT and ERK are downstream. You inhibit a VEGF inhibitor and you're inhibiting AKT and ERK, which we think are important in angiogenesis. And it's expressed on a lot of different cells. And VEGF is also important in normal blood vessel homeostasis and many other things. It inhibits NO, it inhibits NF-kappa B, and so you get a lot of safety side effects. And it's also important in normal vessel homeostasis. And if you inhibit it for a long period of time, you can actually get an increase in bleeding, which is why we think you get waning efficacy with the VEGFs. What's downstream? Well, first of all, where's APJ expressed? Mainly in endothelial cells. That's where the disease is, so you're not inhibiting things in every cell of the body. What's downstream of APJ? AKT. ERK, and also cyclic AMP. And we think all of those may be important in treating patients with AKT. So we think it'll be safer than, for instance, inhibition of AKT, where you're inhibiting AKT in every cell in the body. We think we can get to higher levels of inhibition of AKT. And then we think that the cyclic AMP and the ERK may be important as well.
Speaker 1
Great. And sounds like you're still very confident in sort of that. Pathology-specific selectivity hypothesis after the healthy volunteer data.
Alise Reicin, CEO
Right. So in non-human primates, we went up to 100 mgs per pig, and we saw nothing. It was a 13-week study that the FDA is allowing us to go forward with six-month studies based on a 13-week study. There was no dose-limiting toxicity. Our phase one study, which was single-dose, normal, healthy volunteers, there was really no evidence of an emerging safety issue. We do have a multiple-dose cohort that's completed dosing, and the preliminary data also looks quite good.
Speaker 1
Yeah, makes sense. And, yeah, you mentioned confident in sort of like your dose selection kind of coming out of that healthy volunteer work.
Alise Reicin, CEO
So we approached dose selection. Let's start with target exposure. And we went at it two different ways and came to the same answer, which gives me confidence in it. So what were the two ways? In two different mass models of the disease, and these mass models are much more severe than the human disease. They're homozygotes, in fact. What was the exposure, the minimum exposure that provided maximal efficacy? That's one target exposure. And then in the normal healthy volunteers, we saw something TMDD, which can actually be, it's a measure of strong target engagement of our antibody targeting the APJ receptor, and you can infer receptor occupancy. We said, okay, we want to get to here on receptor occupancy. If we assume that, what would the exposure be? And it was the same exposure that we saw, or it was in the same range of what we saw.
Speaker 1
Yeah.
Alise Reicin, CEO
So now we know that's the target exposure, and then we use the single-dose data to develop a model of what doses would hit that. That would be the mid-dose. Then we'd go to a dose higher, one dose lower. And the multiple-dose cohort was being done just to confirm the model from the single dose. Again, very preliminary data available. Looks like we're in the right range.
Speaker 1
Yeah, great. So, you know, now you're moving into phase 1b, phase 2. Maybe just kind of like help frame out what those studies are in terms of what you're trying to show in them and kind of, you know, what you think is like clinically meaningful on these endpoints.
Alise Reicin, CEO
So the phase 1b study, as I said, is in the severe bleeders. That can be bleeding from the nose, epistaxis, or GI bleeding. And many of them, in fact, will have GI bleeding. And why do I call them severe? It means that they can't keep their hemoglobin up without getting IV iron and or red blood cells transfusions. So we get the baseline, what's their hemoglobin, what are their transfusion requirements. They get put on therapy for six months, and then we're looking for a reduction in the need for those transfusions and either stabilization with a reduction or an improvement in the hemoglobin. And you're looking for about a 30% reduction in the transfusion needs. And if you're just looking at hemoglobin, you'd get about a gram. You'd want to hit those as the targets. And nobody else is looking at that patient population. And there's a lot of interest in that study. It's about 20 patients will be in that study. And I said, we'll be looking at something called the hematologic integrated score, which integrates transfusion rates and hemoglobin. We'll look at hemoglobin, and we'll look at the hematologic support score as well. For patients who have moderate to severe epistaxis, we'll also get frequency, duration, and intensity scores. But some patients in that study may have mild epistaxis because most of their blood loss could be from GI bleeding. And that only has one dose regimen. The phase two study is three-dose regimens, placebo, a one-month run-in to get the baseline e-diary scores, because we'll look at intensity, frequency, and duration. And then it's a 16-week on-treatment period. And we're looking for a minimum of a 15% difference from placebo Placebo treatment difference from placebo. If you look at the ESS, which is the epistaxis severity score, which cannot be used for phase three, but is a validated measure, about 0.71 is what's considered clinically meaningful on that score.
Speaker 1
Yeah. Okay. That's really helpful. And, you know, I think obviously sort of like the benchmark out there people look to is some of like the Videris clinical data. I'm just curious how you like think about that in the context of like where you think kind of like this next wave of drugs is.
Alise Reicin, CEO
That is about the minimum on efficacy. If you look on the ESS, they were about 0.6, just barely meeting that. And if you look as a percentage basin, placebo-adjusted, 10 to 15 percent, depending on the endpoint. For duration, I think they were 20 or 25 percent. I think they were limited on dose by the toxicity. They get to about trough levels of 50% inhibition of AKT. We think if you can get higher, you can get more efficacy out of it.
Speaker 1
Okay, that's helpful. And maybe just like, in that context, there's, you know, AKT1 selective approach, there's a lot of different kind of, you know, mechanisms out there now. Just, you know, it'd be great to kind of like, quickly kind of hear your perspectives on how kind of your approach fits in within sort of this broader landscape of, you know, these different strategies.
Alise Reicin, CEO
A couple of things. Number one, I think that because of the fact that you're not... I think AKT is important, okay? It definitely is important in angiogenesis. But when you use an AKT inhibitor, you're inhibiting AKT in every cell in the body. And I think there's toxicity that goes along with that. And so the question is, with the non-selective inhibitors, you can't get above 50%. We'll have to see how far up on the dose curve they can get with the more selective agents. So that's one thing. The other thing is we think that there are other things downstream of APJ that will also impact HHE treatments, as I said. It's not just AKT. If you look at the AKT inhibitors... In the preclinical models, They have good effects on AVM. Their effects on bleeding are not as good. And we think there may be some things downstream of APJ that are important in vessel architecture and stability. We've shown in the ALK model of HHT, it's an ALK inducible model. The architecture of the endothelial junctions gets disrupted, and so you can imagine you get leaky vessels, which can lead to bleeding, and for instance, the VEGFs don't fix that architecture, but APJ antagonists seem to.
Speaker 1
Awesome. I do want to jump to relaxing because there's obviously a lot to talk about there. Anything else specifically to highlight on HHT that you think is important for people to understand?
Alise Reicin, CEO
Listen, it's a huge unmet need. There's no approved therapies. One of the things that gives me confidence in it is the models have been translated to the clinic. So I think that that provides de-risking that you don't get in all diseases that you go into. So we'll see. We're excited about it.
Speaker 1
Yeah. Okay. Great. Well, you know, with Relaxin, there's obviously so much has happened. This year, like, Relaxin, AstraZeneca had some readouts. Merck and Tenax have been in similar indications. I think, you know, obviously there's been a number of failures with Relaxin specifically. And I think, you know, the biology is so complicated. The patient populations are different. There's so much to unpack. So I guess kind of my question to you is just, what are sort of like your kind of takeaways from this year and how you feel about your thesis?
Alise Reicin, CEO
So I'm going to go back. You know, a year and a half to two years ago, when the only data was available was our phase 1b data, and the Lilly had stopped their study due to an increase in heart failure, right? So we had our phase 1b data where really the hemodynamic effects were spectacular. They exceeded our expectations of them. The drug did everything we could have asked it to do. But what people said is it was a single dose. How do you know you don't have tachyphylaxis from it? Looked by ECHO that things were maintained out to a month, but that was the data we had. The key question was the tachyphylaxis. And then the other key question was, well, look what happened with Lilly. They had an increase in heart failure events. How is relaxin ever going to work in heart failure if it increases the heart failure events? And when we saw the Lilly data, my hypothesis was the dose was too high and they were in the wrong patient population. It was a straight preserved ejection fraction heart failure population, no pulmonary hypertension, and the patients had to have been discharged from the hospital within the last two weeks for worsening heart failure. Those patients with worsening have heart failure. They have fluid retention and sodium retention, and when you discharge them, they're usually still fluid overloaded. They also get treated with IV diuretics in the hospital. That makes them more sodium retentive. That is not a patient population you want to put on relaxin, which can have some sodium and fluid retention associated with that. I really felt those two things are what caused that. Now, here we are. Two years later, the two relaxin programs did not show an increase in heart failure hospitalizations. Our DSMB has met multiple times. There doesn't appear to be a safety issue. And so I think I was right. It was the dose, and it was the patient population. And if you look just at the oral relaxin data, there's no evidence of tachyphylaxis. Even in the HEF-PEF cohort that they had with their oral, you had sustained increases in cardiac output, sustained decreases in systemic vascular resistance out to six months. So those two things, I think, I'm not as worried about them. What the data has shown, though, dose is important, and patient population is important. If you look at the oral relaxin data, the lowest dose was the dose that had the best efficacy. And so I won't be surprised in our study if our 300Q4... It has better efficacy than our 300 Q2. We have a hypothesis that we've chosen a patient population where we're most likely to get the best efficacy. That's patients with half-pef and a PVR greater than 3. And that dose is important. And now, you know, we're just a couple, two months, three months away from getting that data to see if we were right.
Speaker 1
Yeah. Yeah. And I think, you know, maybe on those two points, patient population dose makes total sense. On the patient population, I think your sort of thesis around it being kind of the right test of the relaxant hypothesis is really interesting. Um, maybe just like expand on that a little bit more and why you think. You know, that is really the right patient population and some of the data points here that kind of give us confidence.
Alise Reicin, CEO
I think we're taking advantage of everything relaxant has to offer. So in patients with CPCPH, high PV, why do they have a decreased exercise tolerance? Well, number one, they've got heart failure. And when you have to increase blood coming into the heart and increase cardiac output for when you exercise, pressures go up in the heart, fluid goes into the lung, you get short of breath. In PAH, where you have a high pulmonary vascular resistance, why do you have a decrease in exercise tolerance? Because your vessels are narrowed, and you can't actually get enough blood from the pulmonary circulation into the left side of the heart to increase your cardiac output. CPCPH has both of those defects. We think relaxin, our hypothesis when we went into the phase 1b is we wanted to see the pulmonary vascular resistance go down, and we wanted to see the wedge go down and cardiac output to go up. We saw all of those. And so you're taking advantage of everything relaxin has to offer.
Speaker 1
Yep. Yep. Makes sense. And, you know, I think in the AstraZeneca study... Presumably, they might have had some of these patients.
Alise Reicin, CEO
In the sub-Q study, yeah.
Speaker 1
And this kind of starts to tie into, like, dosing. But, you know, what is sort of your view on whether or not they even, like, tested that CPC hypothesis and specifically PBR grade?
Alise Reicin, CEO
So, first of all... They included HEF-PEF and HEF-REF, and they included IPCPH, normal PVR, and CPCPH. Four different subgroups, there wasn't stratification on any of those subgroups. And you know, you can look at the baseline, you've got unequal distribution of patients. So that's one thing that really complicates this. The other piece is, in terms of PVR greater than 3, in each treatment group, they only had about 35, 30 to 35, I think, patients that had CPCPH, that's PVR greater than 2, and the PI told us only a third of those had a PVR greater than 3. You're talking about 10 to 15 patients in each treatment group divided between HF-PEF and HF-REF. No. We're testing the hypothesis we are testing, which is in PVR greater than 3 and HF-PEF, has not been tested yet.
Speaker 1
Yeah, with relaxant, yeah.
Alise Reicin, CEO
But even there, if you look at their data, where did you start to – I have no idea where they are on the dose curve, by the way. I'm just going to be honest about that. Where did you maybe see a hint of a signal? You saw a PVR reduction in the CPCPH group, and you saw a PVR reduction in the half-path group at the highest dose. I don't know. Maybe that was noise, or maybe it was telling you something.
Speaker 1
And yeah, like you said, we don't know where they were on the dose curve. They didn't really disclose anything.
Alise Reicin, CEO
Yeah, they didn't. They never did renal blood flow. Lily did renal blood flow. We did renal blood flow. So I feel very confident about how to compare myself to them. And they didn't give us, for instance, the hemoglobin data, which would have given us, you know, a look at whether there was any fluid retention.
Speaker 1
Yeah.
Alise Reicin, CEO
So hard to tell.
Speaker 1
Makes sense. And then just kind of like, so, yeah, we have not seen the right test of this. What you are doing, we have not seen sort of the right test. As it relates to DOS, we don't know where AstraZeneca was on the sub-cue. We know the oral, there was the inverse dose response. Maybe just kind of like talk about what you think is the right part of the dose curve and your confidence that you're kind of like in that sweet spot.
Alise Reicin, CEO
I'm not going to get into a lot of detail, but based on what I'm seeing blinded, as well as some phase one data, and what AZ has reported, I think in terms of the fluid retention, we're probably, our 300Q4 is probably about like their 20, or maybe in between their 20 and 80. And our 300Q2 is more likely to be between their mid-dose and their high dose. So I am guessing that if we see efficacy, it will be at the 300Q4 dose. And then we plan to look at exposure response. If we see efficacy at the 300Q4, we're going to look at exposure response and say, if you go even to lower exposures, do you start to see even better efficacy?
Speaker 1
Mm-hmm. And so it's all about threading, like, the right needle here.
Alise Reicin, CEO
I think that, you know, that's the way they've talked about it, and I think they're right.
Speaker 1
Yeah. Okay. And that's just the sort of lower dose. That's just your hypothesis in terms of, like, why, you know, maybe it's. As we've just learned more, it's probably maybe on the better part of the dose curve. Okay. I think, you know, obviously, we've seen with your phase 1b data, there's, you know, a lot of interesting hemodynamic benefits. And I think one of the more interesting things is your patient population is it got better as PBR went up. But I think, like, you know, you address the tachyphylaxis question. But I think naturally, the other question is like, okay, if we see those hemodynamic benefits, they're durable. Will they translate into a clinical benefit? And maybe just help us understand what gives you confidence or at least optimism that that will translate.
Alise Reicin, CEO
Okay. If you look at PAH, there are hundreds of studies where you can, from all of those, look at a correlation between PVR and six-minute walk. We don't have that in CP, CPH. Let's just be honest about that. I also think it's not just PBR. I think PBR is important, but if you have a reduction in PBR, and you're sending more blood into the left side of the heart, and you're not doing anything to improve heart function, you can actually make heart failure worse. So we have to, at a minimum, keep the wedge pressure from going up as well. If you look, though, if you get about a 20% reduction in wedge and regular heart failure, You get about a 20-meter increase in six-minute walk. If you get about a 20% reduction in wedge and a 30% reduction in wedge, That decrease in PVR, which they saw in a very high PVR population in PADN with a surgical procedure called PADN, pulmonary artery denervation, they saw like a 60 to 80 meter increase in six-minute walk. In other words, that combination of bringing down the wedge and bringing down the PVR led to a very dramatic increase in the six-minute walk. No, that's not my bar.
Speaker 1
Yeah. It's not 60 to 80. Yeah.
Alise Reicin, CEO
That was unusual. So tatter sucked. They brought down PVR. They brought down wedge. They saw about a 20-meter increase in six-minute walk, and there was one single center study with a PDE5 inhibitor that saw about a 20% decrease in PVR. They also saw an increase in six-minute walk. My bar is if I can see a 15-meter, people say 15 to 20 meters is what's clinically relevant in this patient population. We're not powered for a six-minute walk, but I want to see a strong numeric trend.
Speaker 1
Yeah, and I wanted to ask about Merck and Sertatercept. That was in a CPC population. Like you said, it was improved wedge pressure, improved PBR, what you've kind of shown, and there was a real six-minute walk benefit. There was an inverse dose response, and my overly simplistic view is that they decreased cardiac output.
Alise Reicin, CEO
I'm with you.
Speaker 1
Is it that simple of why there was maybe an inverse dose response?
Alise Reicin, CEO
I think so. I don't know if I'm right, but I, like you, I said, huh, I wonder if that decrease in cardiac output just, you know, dampened the effect on six-minute walk. Now, of course, our drug increases cardiac output.
Speaker 1
And is it basically like the low dose was? The benefits were enough to kind of overcome that decrease.
Alise Reicin, CEO
Exactly. Exactly.
Speaker 1
Okay.
Alise Reicin, CEO
And then, you know, they saw a really nice effect on time to clinical worsening. And that is now their primary endpoint in their phase three, which gives us some flexibility about how we think about our phase three. We had been focused on six minute walk, but now we're like, well, let's look at the data on time to clinical worsening.
Speaker 1
Yeah.
Alise Reicin, CEO
And we can consider either one, figure out which one would be the most efficient study.
Speaker 1
Yeah, yeah, makes sense. And yeah, I thought that was interesting. But, yeah, maybe it's just, again, going back to kind of six-minute walk, you know, PVR wedge pressure independently associated with six-minute walk benefit. The de-innovation study. It kind of has both. Sertatercept maybe has both, like, all these things kind of showing a consistent, you know, improvement on six-minute walk. 10X obviously also had data this summer. They think, like, they're more severe patients. There was a signal there. Like, what do you make of that, and does that have any bearing on kind of, like, what you're doing or?
Alise Reicin, CEO
I don't think it does. I really think, other than the fact that we decreased preload, too, but I think they have proven that their drug decreases preload. I think that was evident by the reduction in right atrial pressure, and I think the reduction in NT-pro BMP was driven by reduced preload, reduced strain in the heart. But what it looked like is you had two very different patient populations, and it was beneficial in one and it was harmful in the other. I think what could have been going on there, they have already said that the ones that it was beneficial in were probably more fluid overloaded. So I think if you're fluid overloaded and you decrease preload, that's good for the heart, right? It's not as congested, it works, it functions better. On the other hand, if you're uvolemic and you decrease preload too much, it's bad. I think their challenge will be in the clinic, who is it going to help and who is it going to harm? It'll be very interesting to see if the FDA thinks that six-minute walk is going to be the way to do that.
Speaker 1
Yep. Yep. Makes sense. And so, yeah, for APEX, I mean, just kind of like going to the study. Like 15 plus meter, meter plus kind of, you know, benefit would be a win, not expecting any sort of p-value. Like in the context of this time to clinical worsening, I guess like one, are we going to have like any sense of that data over the course of the study or is it too early?
Alise Reicin, CEO
We'll look at outcomes, CV death. Hospitalization for heart failure, outpatient diuretic use, and then the fourth component to that is 15 percent. Um, reduction in six minute walk that's replicated. Now in the, in the Merck phase two study in their phase three, I think they're doing it in their phase three too. If you have a 15% reduction, you're supposed to come in a week later to confirm that we didn't do that in us. So we're going to have to, you know, come up with other ways of looking at that. Like, do you do it on two separate occasions? If you do, you know, um, but We'll have an early look at that data in the phase two.
Speaker 1
Yep. Makes sense. And I guess just like in the context of them using this, like not using six minute walk. Like, is there a scenario where you have, like, really good, you know, hemodynamic benefits, like some signals on outcomes, but six-minute walk is noisy because six-minute walk is noisy?
Alise Reicin, CEO
And maybe we do what they're doing. We do time to clinical worsening in there.
Speaker 1
Yes.
Alise Reicin, CEO
I mean, if you look, the PADN study also, they did just – New England Journal had their Phase III study, which was in a mixed IPC-CPC population. The phase two that I referred to was all CPCPH. The improvement in six-minute walk compared to placebo was not as big in this study, but they had a 50% reduction in time to clinical worsening. But they saw a statistically significant improvement in six-minute walk. So we're going to let the data drive our decision for phase three.
Speaker 1
Yeah. Those kind of takeaways here are right dose, right patient population. We've seen these hemodynamic benefits be durable, and there's evidence to kind of tie that to clinical benefit. And that's sort of the kind of summarization of the optimistic case.
Alise Reicin, CEO
We have a hypothesis. We're testing the hypothesis, and hopefully not too long until we get the data.
Speaker 1
Yeah, and maybe just, I know we're a minute over, but just runway, cash runway, what does that take you guys through?
Alise Reicin, CEO
Cash Runway to first quarter of 2029, which should really cover both getting through our APEX data and CPCPH, Group 2PH, PHILD, and the Phase 1 and the Phase 2 for HHT. And we don't talk a lot about it, but hopefully something else going into IND-enabling studies and into the clinic as well.
Speaker 1
Sounds good. A lot going on. Thanks for joining.
Alise Reicin, CEO
Thank you.